Efficacy of intravenous vitamin-D selective receptor activator [Paricalcitol] in management of secondary Hyperparathyroidism in Hemodialysis patients, single center experience
Egyptian Journal of Hospital Medicine [The]. 2015; 61 (October): 522-528
in English
| IMEMR
| ID: emr-173909
ABSTRACT
Background:
secondary hyperparathyroidism [SHPT], a complication of chronic kidney disease [CKD] and is characterized by not only increased serum levels of intact parathyroid hormone [iPTH], but also may cause skeletal and cardiovascular complications. Deficiency of calcitriol [1, 25-hydroxy vitamin D] caused by impaired renal function, a main factor in the pathogenesis and pathophysiology of secondary hyperparathyroidism [SHPT] is associated with poor outcomes in hemodialysis patients. Therapy with vitamin D receptor [VDR] activators, including calcitriol or the selective VDR activator paricalcitol, has been associated with improved survival in patients with CKD on hemodialysis
Search on Google
Index:
IMEMR (Eastern Mediterranean)
Main subject:
Vitamin D
/
Renal Dialysis
/
Receptors, Calcitriol
/
Disease Management
/
Administration, Intravenous
/
Hyperparathyroidism, Secondary
Limits:
Adult
/
Female
/
Humans
/
Male
Language:
English
Journal:
Egypt. J. Hosp. Med.
Year:
2015
Similar
MEDLINE
...
LILACS
LIS